Who is sponsoring NCT05595226?

NCT05595226 is sponsored by Sheng Liu.

What drugs are being tested in NCT05595226?

Interventions in NCT05595226: RT3D-TEE-guided mitral valve repair.

What condition does NCT05595226 study?

NCT05595226 studies Degenerative Mitral Valve Disease.

Is NCT05595226 still recruiting?

NCT05595226 is currently recruiting now. Last updated 28 October 2022.

Last reviewed 2022-10-28 · How we verify

NCT05595226: TEEMR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of RT3D-TEE-guided Mitral Valve Repair on Outcomes in Patients With Degenerative Mitral Valve Disease

Recruiting now NA Last updated 28 October 2022

What this trial tests

NA trial testing RT3D-TEE-guided mitral valve repair in Degenerative Mitral Valve Disease in 338 participants. Currently enrolling.

Timeline

31 December 2021

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Sheng Liu
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	338
Start date	31 December 2021
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

RT3D-TEE-guided mitral valve repair

Conditions studied

Degenerative Mitral Valve Disease — all drugs for Degenerative Mitral Valve Disease →

Sponsor

Sheng Liu

Who can join

Adults 18 to 80, any sex, with Degenerative Mitral Valve Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this randomized controlled trial to investigate the effects of Real-time 3D transesophageal echocardiography (RT3D-TEE)-guided mitral valve repair on surgical failure and 1-year reoccurrence of mitral valve regurgitation in patients with degenerative mitral value disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Degenerative Mitral Valve Disease

Currently open trials in the same condition.

NCT05655897 — Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or · NA · recruiting
NCT06021509 — Clinical Study of NovoClasp for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation · NA · active not recruiting
NCT03706833 — Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial · NA · active not recruiting
NCT03674593 — Clinical and Fundamental Aspects of Prosthetics and Translocation of Mitral Valve Chordae · NA · active not recruiting

Other Sheng Liu trials

Trials by the same sponsor.

NCT03795740 — Pulmonary Endarterectomy Guided by CT Scanning for Patients With Chronic Thromboembolic Pulmonary Hypertension----PEACT · NA · unknown
NCT03332368 — Clinical Study on Triple Negative Breast Cancer With Chinese Medicine · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05595226 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheng Liu
Last refreshed: 28 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05595226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing